Dynamic quotes: Off
|
Company Description (as filed with the SEC)
Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. Arrowhead is focused on creating new therapeutics that are preferentially taken up by target tissues in order to maximize a drug’s efficacy and potentially limit side effects associated with exposure to healthy cells. Arrowhead has assembled a broad set of technologies and licenses to enable targeted RNAi therapeutics capable of silencing specific gene products in specific cells. Arrowhead has also assembled a proprietary targeting library that may be used with its RNAi platforms as well as with small molecule or peptide drugs. These platforms have yielded several drug candidates under both internal and partnered development. Lead Product Candidates • Adipotide® is an anti-obesity peptide that has been shown to promote weight loss in animal models. ... More ...
Analyst Info |
|
| Annual EPS Est: | $ |
| Quarterly EPS Est: | |
| PEG Ratio: | .00 |
|
Mean Recommendation: View Summary / View All |
1 |
Data is provided by Zacks Investment Research

